IL94888A - Process for reducing the crystalline size of ondanestron hydrochloride dihydrate and pharmaceutical preparations containing them - Google Patents

Process for reducing the crystalline size of ondanestron hydrochloride dihydrate and pharmaceutical preparations containing them

Info

Publication number
IL94888A
IL94888A IL9488890A IL9488890A IL94888A IL 94888 A IL94888 A IL 94888A IL 9488890 A IL9488890 A IL 9488890A IL 9488890 A IL9488890 A IL 9488890A IL 94888 A IL94888 A IL 94888A
Authority
IL
Israel
Prior art keywords
hydrochloride dihydrate
ondansetron hydrochloride
size
crystals
ondansetron
Prior art date
Application number
IL9488890A
Other languages
English (en)
Hebrew (he)
Other versions
IL94888A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL94888(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL94888A0 publication Critical patent/IL94888A0/xx
Publication of IL94888A publication Critical patent/IL94888A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL9488890A 1989-06-28 1990-06-27 Process for reducing the crystalline size of ondanestron hydrochloride dihydrate and pharmaceutical preparations containing them IL94888A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (2)

Publication Number Publication Date
IL94888A0 IL94888A0 (en) 1991-04-15
IL94888A true IL94888A (en) 1995-03-15

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9488890A IL94888A (en) 1989-06-28 1990-06-27 Process for reducing the crystalline size of ondanestron hydrochloride dihydrate and pharmaceutical preparations containing them

Country Status (20)

Country Link
US (1) US5622720A (da)
EP (1) EP0415522B1 (da)
JP (1) JP3093242B2 (da)
KR (1) KR0182789B1 (da)
AT (1) ATE110380T1 (da)
AU (1) AU637110B2 (da)
CA (1) CA2019944C (da)
DE (1) DE69011786T2 (da)
DK (1) DK0415522T3 (da)
ES (1) ES2060045T3 (da)
GB (1) GB8914804D0 (da)
HK (1) HK44495A (da)
HU (1) HU208009B (da)
IE (1) IE64715B1 (da)
IL (1) IL94888A (da)
NZ (1) NZ234267A (da)
RU (1) RU2002745C1 (da)
SA (1) SA90110025B1 (da)
UA (1) UA18249A (da)
ZA (1) ZA905002B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) * 2001-03-12 2002-07-27 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и метацин
HRP20040767A2 (en) * 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
WO2003082804A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
DK1499623T3 (da) 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
UA88186C2 (ru) * 2005-02-23 2009-09-25 Тева Фармасьютикл Индастриз, Лтд. Расагилиновые формуляции с улучшенной однородностью содержимого
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
KR101441459B1 (ko) * 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE460359B (sv) * 1984-01-25 1989-10-02 Glaxo Group Ltd 3-imidazolylmetyltetrahydrokarbazoloner, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
JP2608078B2 (ja) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド 医 薬
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
HU208009B (en) 1993-07-28
EP0415522B1 (en) 1994-08-24
CA2019944A1 (en) 1990-12-28
JPH0395178A (ja) 1991-04-19
US5622720A (en) 1997-04-22
JP3093242B2 (ja) 2000-10-03
DE69011786D1 (de) 1994-09-29
HK44495A (en) 1995-03-31
RU2002745C1 (ru) 1993-11-15
NZ234267A (en) 1992-11-25
IE64715B1 (en) 1995-08-23
DK0415522T3 (da) 1994-09-19
KR0182789B1 (ko) 1999-10-15
ES2060045T3 (es) 1994-11-16
AU637110B2 (en) 1993-05-20
GB8914804D0 (en) 1989-08-16
SA90110025B1 (ar) 2001-03-24
HUT54140A (en) 1991-01-28
CA2019944C (en) 2000-05-09
ATE110380T1 (de) 1994-09-15
HU904015D0 (en) 1990-12-28
IL94888A0 (en) 1991-04-15
ZA905002B (en) 1991-12-24
IE902333L (en) 1990-12-28
EP0415522A1 (en) 1991-03-06
IE902333A1 (en) 1991-01-16
AU5787490A (en) 1991-01-03
KR910000709A (ko) 1991-01-30
DE69011786T2 (de) 1994-12-15
UA18249A (uk) 1997-12-25

Similar Documents

Publication Publication Date Title
AU637110B2 (en) Process for reducing the crystal size of ondanestron hydrochloride dihydrate
US5344658A (en) Process and composition using ondansetron
AU752877B2 (en) Novel crystalline forms of an antiviral benzimidazole compound
RS58600B1 (sr) Fosfonatni analozi jedinjenja hiv inhibitora
EP1390360B1 (en) Crystalline form of omeprazole
WO2018084627A2 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR100573635B1 (ko) 형태 Ⅵ의 5,6-디클로로-2-(이소프로필아미노)-1-(β-Ｌ-리보푸라노실)-1Ｈ-벤즈이미다졸
WO2007092758A2 (en) Crystalline forms of perindopril erbumine
EP1355632B1 (en) Amlodipine free base
MXPA00009734A (en) Novel crystalline forms of an antiviral benzimidazole compound
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
WO2000069417A1 (en) Process for preparing pharmaceutical bulk material having uniform dissolution

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed